Conclusions
coronavirus disease 2019
ASYMPTOMATIC COVID-19, CORONAVIRUS DISEASE 2019
Parenteral remdesivir accelerates viral clearance in early symptomatic COVID-19. Pharmacometric assessment of therapeutics using the method described can determine in vivo clinical antiviral efficacy rapidly and efficiently.In early symptomatic COVID-19, intravenous remdesivir accelerated viral clearance compared with no treatment.Remdesivir has been used extensively as a parenteral treatment for coronavirus disease 2019 (COVID-19) in some regions, although therapeutic recommendations have varied widely [Large randomized controlled trials have since demonstrated the clinical efficacy of multiple small molecule drugs in the treatment of early COVID-19, notably molnupiravir and ritonavir-boosted nirmatrelvir [